<DOC>
	<DOC>NCT00125411</DOC>
	<brief_summary>This is a single center, open-label, non-randomized, Phase I dose finding study of the investigational, oral cytotoxic drug, satraplatin (JM-216), in combination with docetaxel in patients with advanced solid tumors for whom curative therapy is not available. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria. PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors. WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.</brief_summary>
	<brief_title>Study of Satraplatin (JM-216) in Combination With Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative chemotherapy measures do not exist or are no longer effective Life expectancy of at least 3 months Measurable or evaluable disease ECOG performance status of &lt;= 2 Willingness and ability to give informed consent Women who are pregnant or breastfeeding Other chemotherapy treatment less than 4 weeks prior to enrollment Treatment with docetaxel or a platinum agent less than 3 months prior to enrollment Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>satraplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>advanced solid tumors</keyword>
</DOC>